Effect of Prior Aspirin Use on Stroke Severity in the Trial of Org 10172 in Acute Stroke Treatment (TOAST)

Abstract

Background and Purpose-Although the efficacy of aspirin in reducing stroke incidence is clear, its role in reducing stroke severity is disputed. This study compares stroke severity between patients who did or did not take aspirin in the week before stroke and enrollment in the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Methods-Of 1275 patients randomized, 509 reported aspirin use in the week before stroke; 766 did not. Clinical stroke severity was assessed with the National Institutes of Health Stroke Scale (NIHSS) and the Supplementary Motor Examination (SME) at trial entry and at 3 months. Using these scales, we compared the categorization of stroke severity (mild, moderate, and severe) and mean scores between aspirin users and nonusers. Results-The difference in distribution of baseline NIHSS scores was statistically significant between aspirin users and nonusers (Pϭ0.006), with a greater percentage of milder strokes among aspirin users. The difference in mean baseline NIHSS scores was also significantly lower in aspirin users (8.2) and nonusers (9.3) (Pϭ0.003). The distribution of baseline SME scores and mean SME scores also showed lower stroke severity in aspirin users than in nonusers (Pϭ0.048 and Pϭ0.004, respectively). At 3 months, differences in stroke severity measured by the SME but not the NIHSS remained statistically significant. Seven-day and 3-month mortality did not differ significantly. Conclusions-In

Association of Serum Bilirubin with Ischemic Stroke Outcomes

“…All these aforementioned associations have been identified in prior work. [12][13][14][15] Our study has some limitations. This was a single center study, in which patients were not randomized, and we did not collect data on the exact timing of bilirubin levels or stroke severity assessment.…”

“…To evaluate the role of possible confounding factors, other potential determinants of incident stroke severity were also analyzed based on prior reports in the literature: age, sex, history of atrial fibrillation, history of hypertension, hyperlipidemia, diabetes, smoking status, admission glucose, premorbid antithrombotic use, premorbid statin use, and premorbid functional status. [12][13][14][15][16][17] Potential baseline covariate predictors of functional status at hospital discharge included all the aforementioned potential determinants of stroke severity and admission NIHSS score. 12 The pool of potential covariates (listed above) were then selected using backward elimination at P =.2.…”

Hyperglycaemia in acute lacunar stroke: A Chinese hospital-based study

“…The NIHSS score was graded as follows: mild (0-6), medium (7)(8)(9)(10)(11)(12)(13)(14)(15) and severe (≥16). 21 We used the mRS to assess the functional outcome of these patients at 1 year after stroke onset by telephone interview or letter. Unfavourable outcome in terms of dependency or death was defined using the mRS score ≥ 3.…”

Multifunctional Actions of Approved and Candidate Stroke Drugs

“…18,19 Neuroprotection by aspirin was also suggested by clinical studies showing that prestroke use of aspirin reduced stroke severity. 20,21 Increasing evidence suggests that inflammation plays a role both in atherosclerosis with subsequent stroke and in poststroke morbidity and mortality. [22][23][24] Aspirin was found to be associated with lower values of inflammatory parameters after stroke.…”